# An investigation into why people with kidney disease lose muscle and feel weak

Submission date	Recruitment status  No longer recruiting	Prospectively registered		
30/11/2015		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
10/02/2016	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
18/09/2023	Urological and Genital Diseases			

### Plain English summary of protocol

Background and study aims

Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work properly. In a healthy person, the kidneys are vital for filtering out the waste products and excess water in the blood, and converting them into urine. In patients suffering from CKD, the kidneys are unable to do this, and so the body is unable to get rid of the waste products building up in the blood. A common feature of CKD is muscle wasting (when the muscles waste away). This can start early on in the disease, and is thought to play an important role in the way the disease progresses, and even the patients' ultimate chance of survival. It inevitably leads to a poor quality of life and an inactive (sedentary) lifestyle, which in itself can be bad for general health. Currently, the exact cause of muscle wasting in CKD is not really known, and so further research is needed so that it can be better understood and treated. The aim of this study is to grow small pieces of muscle taken from the legs of adult CKD sufferers and healthy adults in the laboratory, in order to find out what is different in the muscle of CKD patients and what the cause of their muscle loss may be. These muscles will also be stretched in the lab to simulate exercise, in order to find out if exercise could have any positive effects.

### Who can participate?

Adults suffering from severe CKD and healthy adults of the same age, sex and race.

# What does the study involve?

All participants have a small sample of muscle tissue taken from their thigh (biopsy) using a needle. They also provide a blood sample and a urine sample at this time. Information about their condition is gathered using a questionnaire at the start of the study, and then again at 6, 12 and 24 months.

What are the possible benefits and risks of participating?

There are no direct benefits for participants taking part in this study. The muscle biopsy carries with it a small risk of bleeding and infection, but to minimise these risks participants taking blood thinners are not able to take part and the procedure will be performed under sterile conditions. The area will ache for a day or so afterwards.

Where is the study run from? Leicester General Hospital (UK)

When is the study starting and how long is it expected to run for? March 2015 to May 2016

Who is funding the study? Kidney Research UK (UK)

Who is the main contact?

1. Dr Alice Smith (Scientific)
aa50@le.ac.uk

2. Dr Emma Watson (Scientific)
ec174@le.ac.uk

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Alice Smith

### **ORCID ID**

http://orcid.org/0000-0002-9234-9060

### Contact details

Leicester Kidney Exercise Team University of Leicester Academic Unit Leicester General Hospital Leicester United Kingdom LE5 5PW +44 (0)1162 584346 aa50@le.ac.uk

### Type(s)

Scientific

### Contact name

Dr Emma Watson

### **ORCID ID**

http://orcid.org/0000-0002-3869-8972

#### Contact details

Lab 117/119 MSB University Road University of Leicester Leicester United Kingdom LE1 9HN +44 (0)1162 525033 ec174@le.ac.uk

# Additional identifiers

### **EudraCT/CTIS** number

Nil known

#### **IRAS** number

187619

### ClinicalTrials.gov number

Nil known

# Secondary identifying numbers

Nil known

# Study information

#### Scientific Title

Mechanisms of muscle wasting in advanced chronic kidney disease

### Acronym

Explore CKD

## Study objectives

The aim of this study is to investigate the mechanisms of muscle wasting in human CKD and their potential to be manipulated by exercise.

### Main research questions:

- 1. How is the molecular control of muscle protein synthesis and degradation modified in CKD and affected by exercise?
- 2. How is the process of myogenesis modified in CKD and affected by exercise?
- 3. Is there a molecular role of microRNA in muscle loss in CKD?

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

NHS East Midlands - Leicester South Research Ethics Committee, 28/11/2015, ref: 15/EM/0467

# Study design

Mechanistic observational laboratory-based study

# Primary study design

Observational

# Secondary study design

Mechanistic observational laboratory-based study

### Study setting(s)

Hospital

### Study type(s)

Other

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet.

### Health condition(s) or problem(s) studied

Chronic kidney disease

#### **Interventions**

A one-off muscle sample will be collected from the leg of CKD patients and matched controls as well as a blood and urine sample. These samples will be used in laboratory experiments to understand the mechanisms of muscle loss in this disease. We will also collect clinical information at 6, 12 and 24 months.

### Intervention Type

Other

### Primary outcome measure

Muscle fibre size is measured using immunohistochemistry.

### Secondary outcome measures

- 1. Differences in the processes of myogenesis measured using flow cytometry, immunohistochemistry and PCR
- 2. Differences in protein turnover measured using uptake and release labelling experiments
- 3. MicroRNA expression and involvement in any dysregulation seen above measured using next generation sequencing and PCR
- 4. Amino acid transport and intracellular concentrations
- 5. Muscle architecture
- 6. Metabolic flexibility and mitochondrial function measured using high resolution respirometry at baseline, 6, 12 and 24 months
- 7. Differences in physical activity levels between groups determined using patient questionnaires at baseline, 6, 12 and 24 months

# Overall study start date

01/01/2016

### Completion date

02/11/2020

# **Eligibility**

### Key inclusion criteria

CKD patients:

1. Over 18 years of age

- 2. Diagnosed CKD stage 3b-5
- 3. If diabetic, good control HbA1c < 9%

Matched controls - will be matched to CKD patients for age, sex and race.

- 1. Over 18 years of age
- 2. Kidney function < 80mL/min/1.73m2
- 3. Good general health

### Participant type(s)

Mixed

### Age group

Adult

### Lower age limit

18 Years

### Sex

Both

# Target number of participants

7

### Total final enrolment

73

### Key exclusion criteria

CKD patients:

- 1. Aged under 18 years
- 2. Uncontrolled diabetes mellitus (HbA1c >9%)
- 3. Inability to give consent for any reason

#### Matched controls:

- 1. Aged under 18 years
- 2. Presence of CKD (eGFR>80mL/min/1.73m2)
- 3. Presence of other diseases known to cause muscle wasting (some cancers, sepsis, burns and HIV)
- 4. Inability to give informed consent for any reason.

### Date of first enrolment

01/01/2015

### Date of final enrolment

02/11/2020

# **Locations**

### Countries of recruitment

England

## **United Kingdom**

# Study participating centre Leicester General Hospital

Gwendolen Road Leicester United Kingdom LE5 4PW

# Sponsor information

# Organisation

University Hospitals of Leicester (UK)

### Sponsor details

R&I Office Leicester General Hospital Gwendolen Road Leicester England United Kingdom LE5 4PW

### Sponsor type

Hospital/treatment centre

#### **ROR**

https://ror.org/02fha3693

# Funder(s)

# Funder type

Charity

### **Funder Name**

Kidney Research UK

# Alternative Name(s)

# **Funding Body Type**

Private sector organisation

# **Funding Body Subtype**

Other non-profit organizations

### Location

United Kingdom

# **Results and Publications**

### Publication and dissemination plan

Planned publication of study results in a peer reviewed journal as well as presentation at national and international conferences.

# Intention to publish date

31/12/2016

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not expected to be made available

### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Plain English results		18/09/2023	18/09/2023	No	Yes
Results article		25/04/2022	18/09/2023	Yes	No
Results article		06/12/2019	18/09/2023	Yes	No
Results article		14/01/2022	18/09/2023	Yes	No